Literature DB >> 16030426

Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.

G Rennert1, S Dishon, H S Rennert, F Fares.   

Abstract

Three specific mutations in the BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT) genes have been reported to be of high prevalence in the Jewish Ashkenazi population. We studied the differences in phenotype of families carrying these mutations. All consecutive families found by the CHS Familial Cancer Service to carry one of the three 'Jewish' mutations of the BRCA1/BRCA2 genes were evaluated for phenotypic characteristics. Chi-squared and Student's t-test statistics were employed to study differences in a variety of clinical and demographic parameters. A total of 111 families with 1499 family members were included. Among them 454 cases of cancer (297 in breast/ovary) were reported. Ovarian cancer, but not breast cancer, was detected at a significantly younger age among carriers of 185delT compared with other mutation carriers. In families with 185delAG, 5382insC and 6174delT mutations, breast cancer was found in 20.2, 39.4 and 24.1% of all identified women (born between 1900 and 1975), correspondingly. The corresponding figures for ovarian cancer were 13.9, 6.8 and 4.9%. Families carrying the 5382insC mutation had the highest probability of expressing bilateral breast cancer (38.9% of families, 15.4% of women with cancer, 6.1% of all women in family) and metachronous breast and ovary tumours (22.2, 9.8 and 4.5% correspondingly). Other tumours were reported in 7.9, 9.1 and 12.0% of women and 9.5, 12.9 and 15.8% of men in families with 185delAG, 5382insC, 6174delT, correspondingly. Marked phenotypic differences were found between families carrying different BRCA mutations warranting mutation-specific counselling to families seeking risk-reduction advice. 5382insC emerged as a most aggressive mutation.

Entities:  

Mesh:

Year:  2005        PMID: 16030426     DOI: 10.1097/00008469-200508000-00008

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

1.  Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.

Authors:  O Lavie; S Narod; F Lejbkowicz; S Dishon; Y Goldberg; O Gemer; G Rennert
Journal:  Ann Oncol       Date:  2010-10-05       Impact factor: 32.976

2.  Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.

Authors:  Soley Bayraktar; Michelle Jackson; Angelica M Gutierrez-Barrera; Diane Liu; Funda Meric-Bernstam; Amanda Brandt; Ashley Woodson; Jennifer Litton; Karen H Lu; Vicente Valero; Banu K Arun
Journal:  Breast J       Date:  2015-03-19       Impact factor: 2.431

3.  BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.

Authors:  Nagi S El Saghir; Nathalie K Zgheib; Hussein A Assi; Katia E Khoury; Yannick Bidet; Sara M Jaber; Raghid N Charara; Rania A Farhat; Firas Y Kreidieh; Stephanie Decousus; Pierre Romero; Georges M Nemer; Ziad Salem; Ali Shamseddine; Arafat Tfayli; Jaber Abbas; Faek Jamali; Muhieddine Seoud; Deborah K Armstrong; Yves-Jean Bignon; Nancy Uhrhammer
Journal:  Oncologist       Date:  2015-03-16

4.  Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK.

Authors:  Dhivya Chandrasekaran; Usha Menon; Gareth Evans; Robin Crawford; Ertan Saridogan; Chris Jacobs; Marc Tischkowitz; Elly Brockbank; Jatinder Kalsi; Davor Jurkovic; Ranjit Manchanda
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

5.  An inherited NBN mutation is associated with poor prognosis prostate cancer.

Authors:  C Cybulski; D Wokołorczyk; W Kluźniak; A Jakubowska; B Górski; J Gronwald; T Huzarski; A Kashyap; T Byrski; T Dębniak; A Gołąb; B Gliniewicz; A Sikorski; J Switała; T Borkowski; A Borkowski; A Antczak; L Wojnar; J Przybyła; M Sosnowski; B Małkiewicz; R Zdrojowy; P Sikorska-Radek; J Matych; J Wilkosz; W Różański; J Kiś; K Bar; P Bryniarski; A Paradysz; K Jersak; J Niemirowicz; P Słupski; P Jarzemski; M Skrzypczyk; J Dobruch; P Domagała; S A Narod; J Lubiński
Journal:  Br J Cancer       Date:  2012-11-13       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.